A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy

Clinical Breast Cancer

Volumn 10, Issue 2, 2010, Pages 148-153

  Pippen, John ^a   Elias, Anthony ^b   Neubauer, Marcus ^c   Stokoe, Christopher ^a   Vaughn, Latrice ^d   Wang, Yanping ^e   Orlando, Mauro ^f   Shonukan, Oluwatoyin ^f   Muscato, Joseph ^g   O'Shaughnessy, Joyce ^a   Gralow, Julie ^h  

^a TEXAS ONCOLOGY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Kansas City Cancer Center   (United States)

^d INDIANA UNIVERSITY   (United States)

^e Lilly USA   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g Missouri Cancer Associates   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Dexamethasone; ER positive; HER positive; Neutropenia; Triple negative; Vitamin B_{12< sub>; Vitamin supplementation}

Indexed keywords

ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; CYANOCOBALAMIN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FOLIC ACID; GEMCITABINE; PEMETREXED; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77950485018     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.020     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
2. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983
3. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339:974-984 (Pubitemid 28455101)
4. Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol 2008; 35(suppl 2):S31-8. (Pubitemid 351503597)
5. Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer 2008; 8(suppl 2):S61-70.
6. Shih C, Grindey GB, Barnett CJ, et al. Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514. Proc Am Assoc Cancer Res 1992; 33:411 (abstract 2452).
7. Grindey GB, Shih C, Barnett CJ, et al. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 1992; 33:411 (abstract 2451).
8. Shih C, Habeck LL, Mendelsohn LG, et al. Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998; 38:135-152 (Pubitemid 28381388)
9. ALIMTA® [complete prescribing information]. Version PV 5205 AMP. Indianapolis, IN: Eli Lilly and Company; revision date October 10, 2008.
10. Bunn P, Paoletti P, Niyikiza C, et al. Vitamin B12 and folate reduce toxicity of ALIMTA® (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 2001; 20:76a (abstract 300).
11. Gomez HL, Santillana SL, Vallejos CS, et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006; 12:832-838
12. Martin M, Spielmann M, Namer M, et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 2003; 14:1246-1252 (Pubitemid 37039051)
13. Spielmann M, Martin M, Namer M, et al. Activity of pemetrexed (ALIMTA® , multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001; 2:47-51. (Pubitemid 32440423)
14. Llombart-Cussac A, Theodoulou M, Rowland K, et al. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study. Clin Breast Cancer 2006; 7:380-385 (Pubitemid 46157558)
15. O'Shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005; 6:143-149 (Pubitemid 40975610)
16. Gemzar® (gemcitabine HCl) for Injection [complete prescribing information]. Version PV 4067 AMP. Indianapolis, IN: Eli Lilly and Company; revision date May 7, 2007.
17. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13:2731-2736
18. Carmichael J, Walling J. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol 1996; 23(suppl 10):77-81. (Pubitemid 26362200)
19. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003; 64:191-206. (Pubitemid 36438803)
20. Possinger K, Kaufmann M, Coleman R, et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999; 10:155-162 (Pubitemid 29141301)
21. Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002; 62:2-8. (Pubitemid 34124219)
22. Valerio MR, Cicero G, Armata MG, et al. Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol 2001; 20:51b (abstract 1953).
23. Gerson R, Serrano A, Villalobos A, et al. Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc Am Soc Clin Oncol 2000; 19: (Abstract 572).
24. Spielmann M, Llombart-Cussac A, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60:303-307 (Pubitemid 32623443)
25. Brodowicz T, Kostler WJ, Möslinger R, et al. Single-agent gemcitabine as secondand third-line treatment in metastatic breast cancer. Breast 2000; 9:338-342
26. Modi S, Currie VE, Seidman AD, et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 2005; 6:55-60. (Pubitemid 40872947)
27. West HL, Wakelee HA, Perry MC, et al. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 2009; 20:850-856
28. Ma CX, Nair S, Thomas S, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5929-5937 (Pubitemid 46300209)
29. Llombart-Cussac A, Martin M, Harbeck N, et al. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res 2007; 13:3652-3659 (Pubitemid 46955129)
30. Ma CX, Steen P, Rowland KM, et al. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Ann Oncol 2006; 17:226-231 (Pubitemid 43160110)
31. Tonkinson JL, Worzalla JF, Teng CH, et al. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59:3671-3676
32. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human nonsmall- cell lung cancer cells. Mol Pharmacol 2005; 68:110-118 (Pubitemid 41002949)
33. Giovannetti E, Mey V, Danesi R, et al. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004; 10:2936-2943 (Pubitemid 38619668)
34. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
35. Dudek AZ, Larson T, McCleod MJ, et al. Phase I/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008; 3:394-399 (Pubitemid 351489480)
36. Robert NJ, Conkling PR, Kuefler PR, et al. Results of a phase II study of pemetrexed as first-line chemotherapy for advanced or metastatic breast cancer. J Clin Oncol 2008; 28(suppl):59s (abstract 1073).
37. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13:2329-2334 (Pubitemid 46698581)